Goodwin’s Life Sciences team will be hosting an upcoming event in our Boston office on March 13, 2024 to spotlight the critical work being done to address the 7,000+ rare diseases that impact more than 300 million people globally.

Join us in person in our Boston office or attend virtually for our Annual Rare Disease Symposium on March 13, 2024. Look forward to an afternoon of engaging fireside chats, inspirational presentations, and networking with your peers in the rare disease community. This year’s program will include speakers covering the patient, advocacy, policy, research, and CEO’s perspectives.

Publicly traded life sciences companies continue to be the primary target of the plaintiffs’ bar, facing far more securities class action lawsuits compared to other sectors. What does this mean for your business, and what practical steps can you take to make informed choices? Join Caroline Bullerjahn, Courtney Orazio, and John Barker as they speak to these pressing issues in Goodwin’s webinar, “2022-2023 Key Trends and Updates: Securities Litigation Against Life Sciences Companies,” taking place on Thursday, June 8^th from 2:30 – 3:30 PM ET.

Register today!

For the first time in decades, the Supreme Court will consider patent law’s “enablement” requirement, in Amgen Inc. v. Sanofi. That requirement is often a key point in litigation when a patent claims a class of novel compounds or antibodies. In the oral argument on March 27, the Supreme Court will examine the Federal Circuit’s holding that patentees must disclose enough information to “enable” people of ordinary skill in the relevant art to “reach the full scope” of the claimed invention. In this day-after webinar, litigators from Goodwin’s Supreme Court and IP Litigation practices will recap the argument and explain what it could mean for the future of the enablement requirement.

Click here to register for the webinar.

CLE credit will be offered for California and New York. 

In global observance of Rare Disease Day, Goodwin invites you to join us for a special awareness event on March 1, 2023 in our Boston office or virtually for those attending remotely to spotlight the critical work being done to address over 7,000 rare diseases that impact more than 300 million people globally.

Goodwin’s Life Sciences Regulatory & Compliance team is bringing together global leaders in the rare disease community for a series of three fireside chats to discuss what inspires them, what challenges continue to face the rare disease community and rare disease patients, the work ahead in the global effort against rare disease, and what we can do to help. Our registration links and full agenda are below, and a networking reception will follow the in-person event in Boston.

A Conversation with Rare Disease Leaders (March 1, 2023) Agenda:

12:00 PM – 12:30 PM EDT | Welcome & Networking Lunch

12:30 PM – 1:00 PM EDT | Fireside Chat – The CEO View

• Justin Klee and Josh Cohen, Co-CEOs & Co-Founders Amylyx (via Zoom)
• Julie Tibbets, Moderator

1:00 PM – 1:30 PM EDT | Fireside Chat – The Patient View

• Bob Coughlin, Managing Director, JLL and Cystic Fibrosis Patient Advocate
• Julie Tibbets, Moderator
• Matt Wetzel, Moderator

1:30 PM – 2:00 PM EDT | Fireside Chat – The Policy View

• Tom DiLenge, Senior Partner, Global Public Policy, Regulatory & Governmental Strategy, Flagship Pioneering (formerly of BIO)
• Matt Wetzel, Moderator

2:00 PM – 2:30 PM EDT | Networking Reception

Click here to register for the in-person event in our Boston offices.

Click here to register for the virtual event.

Goodwin is pleased to invite you to our Life Sciences Disputes webinar series, which will highlight current topics across our Securities Litigation and Antitrust practice areas that affect life sciences companies.

Trends and Hot Topics in Securities Litigation and SEC Enforcement for the Life Sciences Industry
November 9, 2021 – 1:00 pm – 2:00 pm EST

Life sciences and biotech companies are particularly vulnerable to securities class actions due to the variety of event-driven disclosures and the inherently volatile nature of their stock prices. Because of this, over the past several years the biotech and life sciences industries have been the most targeted industries by plaintiffs’ lawyers and a consistent focus of the SEC. Our panel will address the unique securities law disclosure issues facing life sciences companies, particularly with respect to managing risk arising from disclosures of clinical trial results and communications with FDA.

For more information and to register.

FTC Antitrust Lessons Learned for Life Sciences Companies
November 18, 2021 – 2:00 pm – 3:00 pm EST

Over the past several months, Federal Trade Commission (FTC) oversight has been unprecedently high when it comes to exit transactions. Additionally, rules are changing in real time that affect M&A transactions and licensing collaborations, especially in the life sciences industry.

For more information and to register.

In the ever-evolving life sciences industry, compliance is top-of-mind for investors, business leaders, the public and the government.  Life sciences companies are subject to increased enforcement efforts and greater public scrutiny, and boards, investors, and other key stakeholders call for more and better compliance controls.  As a result, there are increased expectations on what compliance programs should cover and what resources should be dedicated to making these programs successful.

With the growing importance of compliance for emerging life sciences companies, Goodwin and the Berkeley Research Group are pleased to announce our inaugural Foundations in Healthcare Compliance series, a multi-part training series where participants will learn from experienced lawyers and professionals about the various considerations when building and growing a compliance program in the life sciences industry.

This five-week series is designed for new compliance officers, in-house counsel or their delegates and investor clients seeking more information about compliance in the life sciences market. We will offer CLE credit for lawyer attendees and non-lawyer compliance certification (HCCA), if available.

For further information and to request an invitation to the series check out the Foundations in Healthcare Compliance mini site.

Goodwin’s 2nd Annual Goodwin + KPMG @ JPMorgan Symposium kicked off Day Two of our Symposium with an overview of the effects of the pandemic on the biopharma market by Dale Raine, Managing Director and Co-Head of the European Healthcare Investment Banking at Lazard in conversation with Goodwin Life Sciences Corporate partner, Graham Defries.  This chat was followed by a panel discussing global life sciences outlook, partnerships and M&A opportunities, and whether Europe will continue to be a focus for 2021 and beyond. The Symposium wrapped up with a fireside chat featuring the Carl Hansen, CEO and Tryn Stimart, CLO of AbCellera in conversation with Goodwin Life Sciences partner Deepa Rich, discussing drug discovery and the accelerated adoption of AI and machine learning in our new reality, and their path to one of the largest IPOs in biotech history.

View the Video

Goodwin held the 2^nd  Annual Goodwin +KPMG @ JPMorgan Symposium on Wednesday, January 27th and Thursday, January 28th. The Symposium kicked off  with industry luminary, Noubar Afeyan, Chairman and Co-Founder of Moderna sitting down for a fireside chat with Vice Chairman, Global Chair of M+A and Goodwin partner, Stuart Cable.

Following the fireside chat, there were three industry focused panels. The first panel, “The COVID Catalyst: Driving Innovation Mainstream,” discussed how COVID-19 boosted innovation across the continuum whether it be devices, therapeutics, diagnostics, supply chain, or the dissemination of needed products and services on a worldwide scale. The second panel, “COVID Gives Digital Health a Shot in the Arm,” addressed how digital health came into the spotlight in 2020 as a result of increased demand for virtual health. The first day wrapped with the panel, “How the 2020 SPACs Revolution Will Impact the IPO Market for 2021 and Beyond,” focused on the rise of SPACs in 2020 and how that will affect the IPO market moving forward.

View the Video:

On February 3, 2021 Goodwin FDA Regulatory partner, Julie Tibbets, Products Litigation + Counseling partner, Nilda Isidro, and Risk Management & Insurance counsel Brian Mukherjee discussed what drug and biologic companies with late-stage product candidates can do to best position their products to mitigate the risks that come with transitioning from clinical trials to marketing and sales.

Our speakers – leaders in life sciences regulatory compliance, product litigation preparedness, risk management, and insurance – highlighted best practices surrounding pharmaceutical promotion, preparing for risks inherent in the marketing and sale of prescription drugs, and the ways in which insurance can help mitigate those risks. This webinar identified key takeaways for companies that are nearing FDA approval and are poised to launch their commercial products.

Click here to view the slides and webinar recording.

Join Goodwin’s Director of Business Development for Life Sciences, Martina Toponarski, as she speaks on a panel of industry experts to discuss how to make the most of JPMorgan 2021 when the conference has gone fully virtual!

For more information and to register for this timely panel, click here.